Previsioni
Il prezzo obiettivo medio degli analisti è 7,59 € (+0,93%). La mediana è 7,29 € (-3,06%).
| Acquista |
6 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
DiaMedica Q2 loss in line with guidance; clinical programs make progress
DiaMedica reported an adjusted loss of $0.19 per share in the second quarter, exactly matching consensus, and no revenue. The biotech company observed significant blood pressure effects in the late preeclampsia study, completed the first cohort in the early fetal growth restriction trial, and has recruited over 85% of patients for the ReMEDy2 stroke interim analysis. Cash and equivalents amounted to $43.5 million as of June 30, which management says should fund operations and studies through 2027, while R&D expenses rose markedly. The stock reacted positively in premarket trading; near‑term milestones include further cohort recruitment, top‑line data and steps toward a U.S. IND submission. » Altro su de.investing.com
1 Main Capital highlights DiaMedica Therapeutics for DM199 stroke‑recovery potential
1 Main Capital said it holds an opportunistic position in DiaMedica Therapeutics, citing DM199, a recombinant form of tissue kallikrein‑1 (KLK1), as a promising therapy for ischemic stroke recovery. The fund noted extensive real‑world use of naturally derived KLK1 in China and positive signals from pooled and Phase 4 studies, while acknowledging those data are not FDA‑caliber and DM199 is not identical to the Chinese product. DiaMedica closed at $6.34 on July 31, 2026, with a market cap near $342 million and mixed recent returns. » Altro su finance.yahoo.com
DiaMedica Therapeutics strengthens liquidity and reports slightly better EPS for Q4 2025
DiaMedica Therapeutics reported Q4 2025 EPS of -$0.17, slightly above expectations, and increased cash and equivalents to $59.9 million (+35.8%). Operating cash outflow rose due to higher R&D spending, including the expansion of the ReMEDy2 study. Management expects current liquidity to fund operations through the end of 2027; the stock fell 2.21% in after-hours trading. » Altro su de.investing.com
DiaMedica receives Health Canada approval for phase-2 study of DM199 in early-onset preeclampsia
DiaMedica has received a 'No Objection Letter' from Health Canada to start an open-label phase-2 dose-finding study of DM199 in early-onset preeclampsia. The study, planned for 2026, will test three dose levels, administer DM199 subcutaneously every three days until delivery, and assess safety, tolerability and exploratory efficacy markers such as pulsatility index, sFlt‑1 and placental growth factor. The company plans to expand the study to the US and the UK after regulatory clearances. According to the data, DiaMedica shows high short-term liquidity; analysts have price targets between $11 and $25, while InvestingPro currently considers the stock overvalued. » Altro su de.investing.com
DiaMedica must conduct additional non-clinical study for DM199 after FDA talks
The FDA requires, before an IND filing for treatment of early-onset preeclampsia, a 10-day modified embryo‑fetal plus pre- and postnatal study in rabbits, with results expected by Q2 2026. DiaMedica announced it will carry out this study for its drug DM199 (Rinvecalinas‑Alfa) and said the talks provided regulatory clarity on the non-clinical data package. At the same time, an investigator-initiated phase‑2 trial in South Africa is already treating more than 30 women with late-stage preeclampsia; preliminary data show encouraging safety and efficacy signals. Analysts have lowered their earnings estimates following the news, and the stock has recently fallen. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2022, DIAMEDICA THERAPEUT. ha già distribuito 2,74 € di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.
Dati finanziari
Nell'ultimo trimestre, DIAMEDICA THERAPEUT. ha registrato ricavi pari a 0 € e un utile netto di -9,99 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -9,99 Mln | 35,94% |
| EBITDA | -9,97 Mln | 36,08% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 405,69 Mln € |
Numero di azioni | 53,96 Mln |
Massimo/minimo a 52 settimane | 10,02 € - 4,78 € |
| Dividendi | No |
Beta | 0,94 |
Rapporto P/E | -10,86 |
Rapporto PEG | 1,57 |
Rapporto P/B | 15,53 |
Rapporto P/S | 0,00 |
Profilo aziendale
DiaMedica Therapeutics Inc., una società biofarmaceutica in fase clinica, sviluppa trattamenti per malattie neurologiche e renali. Il principale candidato farmaco della società è DM199, una proteina ricombinante della calicreina-1 tissutale umana, che è in fase 2 nel trial REDUX per il trattamento di pazienti con malattia renale cronica da moderata a grave causata dal diabete di tipo I o di tipo II; e in trial di fase 2/3 REMEDY2 per il trattamento di pazienti con ictus ischemico acuto. La società sta inoltre sviluppando DM300, che si trova in fase preclinica per il trattamento di malattie infiammatorie. La società era precedentemente nota come DiaMedica Inc. e ha cambiato denominazione in DiaMedica Therapeutics Inc. nel dicembre 2016. DiaMedica Therapeutics Inc. è stata costituita nel 2000 e ha sede a Minneapolis, Minnesota.
| Nome | DIAMEDICA THERAPEUT. |
| CEO | Dietrich John Pauls |
| Sede centrale | Minneapolis,
mn Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 03/08/2012 |
| Dipendenti | 35 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | DMAC |